⌕
Wave Life Sciences · WVE · Nasdaq
Tenet 54 · Mixed
Compare
$2.87−8.31%At closeTenet 54 · Mixed
$2.87−0.26 (−8.31%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Wave Life Sciences (WVE) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 62% below its peak, net margin −478.3%. Worth your attention in FY25: Share count (+177.2%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼60.5%
42.7
FY21→FY25CAGR +1.1%/yr
Net income ($M)▼110.7%
−204.4
FY21→FY25CAGR —
Free cash flow ($M)▼23.9%
−188.2
FY21→FY25CAGR —
Diluted EPS▼72.9%
−1.21
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+177.2%

60.8mn → 168.6mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$718.0K

−23.5% YoY in FY25 · 1.7% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)42.7Revenue0.0COGS42.7Gross profit−182.8R&D−75.3SG&A−215.4Op income11.0Tax & other−204.4Net income

-478¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%FY21FY25

Over this window: gross 100.0% → 100.0%. Net margin -478.3% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
70,921.042,727.0108,302.0113,305.03,649.040,964.0▼60.5%+1.1%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
70,921.042,727.0108,302.0113,305.03,649.040,964.0▼60.5%+1.1%
Research & development
205,390.0182,779.0159,682.0130,009.0115,856.0121,875.0▲14.5%+10.7%
Selling, general & admin
93,145.075,331.059,023.051,292.050,513.046,105.0▲27.6%+13.1%
Total operating expenses
298,535.0258,110.0218,705.0181,301.0166,369.0167,980.0▲18.0%+11.3%
Operating incomefeeds ROC rank
−227,614.0−215,383.0−110,403.0−67,996.0−162,720.0−127,016.0▼95.1%—
Other income, net
17,081.011,005.013,395.09,806.01,578.04,567.0——
Pretax income
−210,533.0−204,378.0−97,008.0−58,190.0−161,142.0−122,449.0▼110.7%—
Income tax
—0.00.0−677.0681.0−204.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−210,533.0−204,378.0−97,008.0−57,513.0−161,823.0−122,245.0▼110.7%—
Per share
Diluted EPSbuyback-sensitive
−1.06−1.21−0.70−0.54−2.05−2.36▼72.9%—
Diluted shares (mn)
204.22168.65138.28106.1078.8660.84▲22.0%+29.0%
Margins
Gross margin82nd pct in Healthcare
100.0%100.0%100.0%100.0%100.0%100.0%▲0.0pp+0.0pp
Operating margin
−320.9%−504.1%−101.9%−60.0%−4459.3%−310.1%▼402.2pp−194.0pp
Net margin13th pct in Healthcare
−296.9%−478.3%−89.6%−50.8%−4434.7%−298.4%▼388.8pp−179.9pp
† TTM = trailing four quarters through 2026-09-30.
FY16 – FY20 · 5 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Wave Life Sciences' revenue last fiscal year?

Wave Life Sciences reported revenue of $42.7M in fiscal 2025, down 60.5% from fiscal 2024.

What was Wave Life Sciences' net income?

Wave Life Sciences reported net income of −$204.4M in fiscal 2025, a net margin of −478.3%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.